Letter: NSBB for fatty liver disease-Still a long way to go

Aliment Pharmacol Ther. 2023 Oct;58(8):847. doi: 10.1111/apt.17692.

Authors

Hangfei Xu^{1

2}, Yang Zhang², Jing Zhang¹

Affiliations

¹ The Third Unit, Department of Hepatology, Beijing Youan Hospital, affiliated with Capital Medical University, Beijing, China.
² Beijing Institute of Hepatology, Beijing Youan Hospital, Capital Medical University, Beijing, China.

PMID: 37768286
DOI: 10.1111/apt.17692

No abstract available

Publication types

Letter
Comment

MeSH terms

Adrenergic beta-Antagonists*
Humans
Liver Cirrhosis*

Substances

Adrenergic beta-Antagonists